StockIQ.techVertex Pharmaceuticals Inc. (VRTX) Stock Analysis
Free AI-powered analysis and research for Vertex Pharmaceuticals Inc. stock
Sector: Healthcare
VRTX snapshot
Data as of 3 Nov 2026 close. Updated daily.
Vertex Pharmaceuticals Inc. scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 78% of its 52-week range, up 25.1% over the past year. Latest reported figures show a profit margin of 35.0%, return on equity of 23.5% and revenue growth of +12.5%.
What is driving the score
- RSI Neutral: +5
- Uptrend: +3
- MACD Bullish: +8
- High P/E (30.2): -10
- Excellent Profit Margin (35.0%): +10
- Low Debt (0.10 D/E): +8
- Strong Liquidity (3.19 Current Ratio): +8
- Excellent ROE (23.5%): +8
- High P/B (6.63): -5
- Strong Long-term Uptrend: +8
- Healthy Momentum (+25.1% over 1 year): +7
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full VRTX report
Vertex Pharmaceuticals Inc. (VRTX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze VRTX Now →📰 Latest Update
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Tue, November 3, 2026 at 2:02 PM UTC 2 min read
Vertex Pharmaceuticals (VRTX) reported Q3 2026 adjusted earnings of $4.76 per share, falling short of the Zacks Consensus Estimate of $4.92, while total revenues of $3.44 billion exceeded expectations. The revenue growth of 12% year over year was driven by increased sales of cystic fibrosis drugs and new products, prompting Vertex to raise its full-year revenue guidance to $13.15-$13.25 billion. Despite the earnings miss, the company's shares have risen 22% year to date.